|
Video: What is a Stock Split?
|
|
Entrada Therapeutics is a biotechnology company. Co. is focused on the development of Endosomal Escape Vehicle (EEV) therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1. In its neuromuscular disease programs, Co. links EEVs to small strands of nucleic acids called oligonucleotides, including phosphorodiamidate morpholino oligomers (PMOs). Co. is developing EEV-PMOs that promote the skipping of these mutations associated with DMD. Co.'s therapeutic candidate, ENTR-601-44, is being developed for patients with DMD that are exon 44 skipping amenable. According to our Entrada Therapeutics stock split history records, Entrada Therapeutics has had 0 splits. | |
|
Entrada Therapeutics (TRDA) has 0 splits in our Entrada Therapeutics stock split history database.
Looking at the Entrada Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Entrada Therapeutics shares, starting with a $10,000 purchase of TRDA, presented on a split-history-adjusted basis factoring in the complete Entrada Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/01/2021 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$22.51 |
|
End price/share: |
$12.45 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-44.69% |
|
Average Annual Total Return: |
-21.21% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,530.16 |
|
Years: |
2.48 |
|
|
|
|
|